[{"id":"4bf9de82-bc5d-4f41-96c1-1ff5dcf642d4","acronym":"","url":"https://clinicaltrials.gov/study/NCT05672524","created_at":"2023-01-05T14:58:33.539Z","updated_at":"2024-07-02T16:35:09.423Z","phase":"Phase 2","brief_title":"A Study of Tucatinib and Trastuzumab in People With Rectal Cancer","source_id_and_acronym":"NCT05672524","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" HER-2 • KRAS","pipe":" | ","alterations":" HER-2 positive • HER-2 overexpression • HER-2 amplification • RAS wild-type • KRAS exon 2 mutation • RAS wild-type + HER-2 positive • KRAS exon 3 mutation • KRAS exon 4 mutation","tags":["HER-2 • KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HER-2 overexpression • HER-2 amplification • RAS wild-type • KRAS exon 2 mutation • RAS wild-type + HER-2 positive • KRAS exon 3 mutation • KRAS exon 4 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • Tukysa (tucatinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 37","initiation":"Initiation: 12/30/2022","start_date":" 12/30/2022","primary_txt":" Primary completion: 12/30/2025","primary_completion_date":" 12/30/2025","study_txt":" Completion: 12/30/2025","study_completion_date":" 12/30/2025","last_update_posted":"2024-04-16"},{"id":"939cf6e0-4581-41cd-811a-c9f07aba8b51","acronym":"STRATEGIC-1","url":"https://clinicaltrials.gov/study/NCT01910610","created_at":"2021-01-18T08:36:45.253Z","updated_at":"2024-07-02T16:35:15.367Z","phase":"Phase 3","brief_title":"Multi-Line Therapy Trial in Unresectable Metastatic Colorectal Cancer","source_id_and_acronym":"NCT01910610 - STRATEGIC-1","lead_sponsor":"GERCOR - Multidisciplinary Oncology Cooperative Group","biomarkers":" KRAS • NRAS","pipe":" | ","alterations":" NRAS mutation • KRAS wild-type • RAS mutation • RAS wild-type • NRAS wild-type • KRAS exon 3 mutation • KRAS exon 4 mutation","tags":["KRAS • NRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NRAS mutation • KRAS wild-type • RAS mutation • RAS wild-type • NRAS wild-type • KRAS exon 3 mutation • KRAS exon 4 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • Erbitux (cetuximab) • 5-fluorouracil • Vectibix (panitumumab) • capecitabine • oxaliplatin • irinotecan • leucovorin calcium"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 464","initiation":"Initiation: 10/30/2013","start_date":" 10/30/2013","primary_txt":" Primary completion: 07/13/2023","primary_completion_date":" 07/13/2023","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2024-03-11"},{"id":"fe7d37d6-22f3-4c41-9187-22556cd9ff0c","acronym":"","url":"https://clinicaltrials.gov/study/NCT04169347","created_at":"2021-01-18T20:20:29.434Z","updated_at":"2024-07-02T16:35:41.893Z","phase":"Phase 2","brief_title":"FOLFOXIRI Plus Panitumumab in Metastatic RAS Wild-type, Left-sided Colorectal Cancer","source_id_and_acronym":"NCT04169347","lead_sponsor":"Criterium, Inc.","biomarkers":" KRAS","pipe":" | ","alterations":" KRAS wild-type • RAS wild-type • KRAS exon 2 mutation • KRAS exon 2 wild-type • KRAS exon 3 mutation • KRAS exon 4 mutation","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS wild-type • RAS wild-type • KRAS exon 2 mutation • KRAS exon 2 wild-type • KRAS exon 3 mutation • KRAS exon 4 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e 5-fluorouracil • Vectibix (panitumumab) • oxaliplatin • irinotecan • leucovorin calcium"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 27","initiation":"Initiation: 12/02/2019","start_date":" 12/02/2019","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 01/01/2025","study_completion_date":" 01/01/2025","last_update_posted":"2023-07-27"},{"id":"2f454d62-b561-48df-9aa8-c95f396adca9","acronym":"VOLFI","url":"https://clinicaltrials.gov/study/NCT01328171","created_at":"2021-01-18T05:24:48.418Z","updated_at":"2024-07-02T16:35:45.737Z","phase":"Phase 2","brief_title":"FOLFOXIRI With or Without Panitumumab in Metastatic Colorectal Cancer (VOLFI)","source_id_and_acronym":"NCT01328171 - VOLFI","lead_sponsor":"AIO-Studien-gGmbH","biomarkers":" EGFR • KRAS • PIK3CA • NRAS • PTEN • ERCC1 • RAS • MTHFR","pipe":" | ","alterations":" EGFR mutation • PIK3CA mutation • KRAS wild-type • RAS wild-type • EGFR exon 18 mutation • KRAS exon 2 mutation • EGFR mutation + PIK3CA mutation • KRAS exon 2 wild-type • KRAS exon 3 mutation • KRAS exon 4 mutation","tags":["EGFR • KRAS • PIK3CA • NRAS • PTEN • ERCC1 • RAS • MTHFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • PIK3CA mutation • KRAS wild-type • RAS wild-type • EGFR exon 18 mutation • KRAS exon 2 mutation • EGFR mutation + PIK3CA mutation • KRAS exon 2 wild-type • KRAS exon 3 mutation • KRAS exon 4 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e 5-fluorouracil • Vectibix (panitumumab) • oxaliplatin • irinotecan • leucovorin calcium"],"overall_status":"Completed","enrollment":" Enrollment 93","initiation":"Initiation: 04/01/2011","start_date":" 04/01/2011","primary_txt":" Primary completion: 06/01/2017","primary_completion_date":" 06/01/2017","study_txt":" Completion: 01/01/2022","study_completion_date":" 01/01/2022","last_update_posted":"2023-06-14"},{"id":"0fedf5e9-36db-42c2-931a-e84983c3f809","acronym":"PIER","url":"https://clinicaltrials.gov/study/NCT03000374","created_at":"2021-01-18T14:45:36.710Z","updated_at":"2024-07-02T16:36:15.193Z","phase":"Phase 2","brief_title":"Induction Therapy With Panitumumab + mFOLFOX-6 in Rectal Cancer and Quadruple Wild-type Mutation Before Surgery","source_id_and_acronym":"NCT03000374 - PIER","lead_sponsor":"Grupo Espanol Multidisciplinario del Cancer Digestivo","biomarkers":" KRAS • BRAF • NRAS","pipe":" | ","alterations":" KRAS exon 3 mutation • KRAS exon 4 mutation • BRAF exon 15 mutation","tags":["KRAS • BRAF • NRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS exon 3 mutation • KRAS exon 4 mutation • BRAF exon 15 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e 5-fluorouracil • Vectibix (panitumumab) • oxaliplatin • leucovorin calcium"],"overall_status":"Completed","enrollment":" Enrollment 34","initiation":"Initiation: 05/30/2017","start_date":" 05/30/2017","primary_txt":" Primary completion: 10/31/2020","primary_completion_date":" 10/31/2020","study_txt":" Completion: 12/15/2021","study_completion_date":" 12/15/2021","last_update_posted":"2022-03-17"},{"id":"233d1a7a-82a0-458e-922e-f1c6e41a5507","acronym":"","url":"https://clinicaltrials.gov/study/NCT02301962","created_at":"2021-01-18T10:52:59.527Z","updated_at":"2024-07-02T16:36:52.433Z","phase":"Phase 4","brief_title":"Phase IV Panitumumab Study in Indian Subjects With Metastatic Colorectal Cancer","source_id_and_acronym":"NCT02301962","lead_sponsor":"Dr. Reddy's Laboratories Limited","biomarkers":" KRAS • NRAS","pipe":" | ","alterations":" NRAS mutation • KRAS wild-type • RAS wild-type • NRAS wild-type • KRAS exon 2 wild-type • KRAS exon 3 mutation • KRAS exon 4 mutation","tags":["KRAS • NRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NRAS mutation • KRAS wild-type • RAS wild-type • NRAS wild-type • KRAS exon 2 wild-type • KRAS exon 3 mutation • KRAS exon 4 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Vectibix (panitumumab)"],"overall_status":"Unknown status","enrollment":" Enrollment 58","initiation":"Initiation: 07/28/2015","start_date":" 07/28/2015","primary_txt":" Primary completion: 06/30/2021","primary_completion_date":" 06/30/2021","study_txt":" Completion: 01/31/2022","study_completion_date":" 01/31/2022","last_update_posted":"2019-12-16"},{"id":"6dd064ce-a694-4785-a251-cdfbdd1c7abc","acronym":"","url":"https://clinicaltrials.gov/study/NCT03101839","created_at":"2021-01-18T15:16:55.418Z","updated_at":"2024-07-02T16:36:54.847Z","phase":"Phase 1","brief_title":"Phase I Dose-Escalation Study of AZD4785 in Patients With Advanced Solid Tumours","source_id_and_acronym":"NCT03101839","lead_sponsor":"AstraZeneca","biomarkers":" KRAS","pipe":" | ","alterations":" KRAS mutation • KRAS G12 • KRAS A146 • KRAS Q61 • KRAS A59 • KRAS K117 • KRAS exon 3 mutation • KRAS exon 4 mutation","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • KRAS G12 • KRAS A146 • KRAS Q61 • KRAS A59 • KRAS K117 • KRAS exon 3 mutation • KRAS exon 4 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AZD4785"],"overall_status":"Completed","enrollment":" Enrollment 28","initiation":"Initiation: 05/15/2017","start_date":" 05/15/2017","primary_txt":" Primary completion: 01/08/2019","primary_completion_date":" 01/08/2019","study_txt":" Completion: 01/08/2019","study_completion_date":" 01/08/2019","last_update_posted":"2019-10-04"},{"id":"3ec8e60a-4c4a-4207-8e19-aa5bc6a8cbfe","acronym":"FORBES","url":"https://clinicaltrials.gov/study/NCT02350530","created_at":"2021-01-18T11:10:51.881Z","updated_at":"2024-07-02T16:37:28.971Z","phase":"Phase 2","brief_title":"FOLFOXIRI With or Without Bevacizumab as First-line Treatment for Unresectable Liver-only Metastatic Colorectal Cancer Patients With RAS Mutation-type","source_id_and_acronym":"NCT02350530 - FORBES","lead_sponsor":"Sun Yat-sen University","biomarkers":" KRAS • NRAS","pipe":" | ","alterations":" KRAS exon 2 mutation • KRAS exon 3 mutation • KRAS exon 4 mutation","tags":["KRAS • NRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS exon 2 mutation • KRAS exon 3 mutation • KRAS exon 4 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • 5-fluorouracil • oxaliplatin • irinotecan • leucovorin calcium"],"overall_status":"Unknown status","enrollment":" Enrollment 138","initiation":"Initiation: 01/01/2015","start_date":" 01/01/2015","primary_txt":" Primary completion: 01/01/2018","primary_completion_date":" 01/01/2018","study_txt":" Completion: 01/01/2020","study_completion_date":" 01/01/2020","last_update_posted":"2016-09-20"},{"id":"bb9befbe-d504-4088-a29d-3fbc50540911","acronym":"","url":"https://clinicaltrials.gov/study/NCT01668498","created_at":"2021-01-18T07:12:58.663Z","updated_at":"2024-07-02T16:37:32.678Z","phase":"Phase 2","brief_title":"Comparison of Two Preemptive Treatment Strategies of Panitumumab Mediated Skin Toxicity and Assessment of QoL in Patient With Ras-wt Colorectal Cancer","source_id_and_acronym":"NCT01668498","lead_sponsor":"AIO-Studien-gGmbH","biomarkers":" KRAS • RAS","pipe":" | ","alterations":" KRAS wild-type • RAS wild-type • NRAS wild-type • KRAS exon 2 mutation • KRAS exon 2 wild-type • KRAS exon 3 mutation • KRAS exon 4 mutation","tags":["KRAS • RAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS wild-type • RAS wild-type • NRAS wild-type • KRAS exon 2 mutation • KRAS exon 2 wild-type • KRAS exon 3 mutation • KRAS exon 4 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Vectibix (panitumumab)"],"overall_status":"Completed","enrollment":" Enrollment 88","initiation":"Initiation: 05/01/2011","start_date":" 05/01/2011","primary_txt":" Primary completion: 01/01/2015","primary_completion_date":" 01/01/2015","study_txt":" Completion: 03/01/2016","study_completion_date":" 03/01/2016","last_update_posted":"2016-04-19"}]